Journal
ONCOGENE
Volume 29, Issue 26, Pages 3733-3744Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.139
Keywords
mTOR; mTORC2; AKT; SGK; rapamycin; Rictor
Funding
- National Institutes of Health [R00 CA129613]
- Charles Hood Foundation
- UMass Center for Clinical and Translational Sciences
Ask authors/readers for more resources
Small molecule inhibitors that selectively target cancer cells and not normal cells would be valuable anti-cancer therapeutics. The mammalian target of rapamycin complex 2 (mTORC2) is emerging as a promising candidate target for such an inhibitor. Recent studies in cancer biology indicate that mTORC2 activity is essential for the transformation and vitality of a number of cancer cell types, but in many normal cells, mTORC2 activity is less essential. These studies are intensifying interest in developing inhibitors that specifically target mTORC2. However, there are many open questions regarding the function and regulation of mTORC2 and its function in both normal and cancer cells. Here, we summarize exciting new research into the biology of mTORC2 signaling and highlight the current state and future prospects for mTOR-targeted therapy. Oncogene (2010) 29, 3733-3744; doi: 10.1038/onc.2010.139; published online 26 April 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available